Drugs that contain Docetaxel
1. Docetaxel patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10842770 | SHILPA | Non-aqueous taxane pro-emulsion formulations and methods of making and using the same |
Aug, 2031
(7 years from now) | |
| US8940786 | SHILPA | Non-aqueous taxane nanodispersion formulations and methods of using the same |
Sep, 2033
(9 years from now) | |
| US9308195 | SHILPA | Non-aqueous taxane formulations and methods of using the same |
Sep, 2033
(9 years from now) | |
| US9763880 | SHILPA | Non-aqueous taxane formulations and methods of using the same |
Sep, 2033
(9 years from now) | |
Market Authorisation Date: 22 December, 2015
Treatment: Method of administering docetaxel to a subject combining the docetaxel pro-emulsion formulation with an aqueous medium to produce docetaxel emulsion; Method of administering an ethanol-free taxane liq...
Dosage: INJECTABLE;INJECTION
More Information on Dosage
DOCETAXEL family patents
2. Docetaxel patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10398785 | INGENUS PHARMS LLC | Pharmaceutical compositions containing taxane-cyclodextrin complexes, method of making and methods of use |
Mar, 2036
(11 years from now) | |
Market Authorisation Date: 22 November, 2022
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
More Information on Dosage
DOCETAXEL family patents
3. Taxotere patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5698582 | SANOFI AVENTIS US | Compositions containing taxane derivatives |
Jul, 2012
(11 years ago) | |
| US5750561 | SANOFI AVENTIS US | Compositions containing taxane derivatives |
Jul, 2012
(11 years ago) | |
| US5714512 | SANOFI AVENTIS US | Compositions containing taxane derivatives |
Jul, 2012
(11 years ago) | |
|
US5750561 (Pediatric) | SANOFI AVENTIS US | Compositions containing taxane derivatives |
Jan, 2013
(11 years ago) | |
|
US5714512 (Pediatric) | SANOFI AVENTIS US | Compositions containing taxane derivatives |
Jan, 2013
(11 years ago) | |
|
US5698582 (Pediatric) | SANOFI AVENTIS US | Compositions containing taxane derivatives |
Jan, 2013
(11 years ago) | |
| US5438072 | SANOFI AVENTIS US | Taxoid-based compositions |
Nov, 2013
(10 years ago) | |
|
US5438072 (Pediatric) | SANOFI AVENTIS US | Taxoid-based compositions |
May, 2014
(9 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Nov 13, 2013 |
| M(M-61) | May 13, 2013 |
Market Authorisation Date: 03 August, 2010
Treatment: NA
Dosage: INJECTABLE;INJECTION
How can I launch a generic of TAXOTERE before it's drug patent expiration?
More Information on Dosage
TAXOTERE family patents